On September 10, 2020 Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, reported that Clive Richardson, Chief Executive Officer, will participate and host investor meetings during the following upcoming virtual investor conferences (Press release, Akari Therapeutics, SEP 10, 2020, View Source [SID1234564952]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Event: H.C. Wainwright 22nd Annual Global Investment Conference
Date: Tuesday, September 15, 2020
Presentation: 1:30 p.m. ET
Event: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: Wednesday, September 23, 2020
Presentation: 10:50 a.m. ET
Investors interested in arranging a virtual meeting with the Company’s management during either conference should contact the respective conference coordinator.
A live webcast and subsequent archived recording of each presentation will be available by visiting ‘Events’ in the Investor Relations section on the Company’s website at www.akaritx.com.